NEWS
Bridgepoint expands aesthetics portfolio with Obagi [June 2026]
Private equity investment continues to reshape the aesthetics market, with Bridgepoint adding Obagi Medical to a portfolio that already includes Laboratoires Vivacy.
Bridgepoint has completed its acquisition of a majority stake in Obagi Medical, adding the medical-grade skincare business to a growing healthcare and aesthetics portfolio.
The investment firm first announced the deal in June 2026, with the transaction completing in the third quarter of the year.
Obagi Medical operates across North America, Europe, Asia and the Middle East through dermatologists, aesthetic practitioners and other healthcare professionals.
The acquisition is particularly notable because Bridgepoint already owns Laboratoires Vivacy, the French manufacturer behind the Stylage dermal filler portfolio.
Bridgepoint acquired Vivacy in 2023 and describes the company as a leading developer of hyaluronic acid-based injectable products, with distribution in more than 85 countries.
A broader aesthetics strategy
Bridgepoint has made clear that it sees further opportunity across dermatology, skincare and medical aesthetics.
In announcing the Obagi transaction, the investment firm specifically referenced its existing investment in Vivacy and said it saw opportunities for future partnership between the businesses.
That creates an increasingly broad professional-aesthetics platform spanning both injectables and physician-led skincare.
Obagi has also expanded beyond skincare. In 2025 it acquired Novaestiq, followed by the 2026 launch of the FDA-approved Obagi Saypha MagIQ dermal filler line.
Why it matters
The transaction follows a wider pattern of investment activity across aesthetics.
In the UK, Healthxchange recently announced investment from Growth Partner, while international investors continue to target manufacturers, clinic groups, skincare businesses and other parts of the aesthetics supply chain.
Taken together, the deals suggest investors increasingly view medical aesthetics not simply as a collection of independent clinics and product manufacturers, but as a maturing healthcare and consumer market capable of supporting larger, integrated businesses.
The Harley Take
The interesting story is not simply that Obagi has changed ownership.
It is the increasingly connected portfolio being built around professional aesthetics.
With Vivacy providing an established injectables platform and Obagi bringing physician-led skincare — alongside its own move into fillers — Bridgepoint now has exposure across several parts of the patient journey.
For clinics, manufacturers and distributors, that raises a bigger question:
Are we entering a period where consolidation creates a smaller number of significantly larger aesthetics platforms?
It is a theme worth watching — particularly alongside recent investment into businesses such as Healthxchange.
Sources
Bridgepoint — “Bridgepoint agrees to acquire Obagi Medical”
2 June 2026.
https://www.bridgepointgroup.com/about-us/news-and-insights/press-releases/2026/bridgepoint-agrees-to-acquire-obagi-medicalBridgepoint — Obagi Medical Portfolio
Confirms the transaction completed in Q3 2026 and provides background on the business.
https://www.bridgepointgroup.com/investment-strategies/private-equity/portfolio/middle-market/healthcare/obagi-medicalBridgepoint — Laboratoires Vivacy Portfolio
Background on Bridgepoint's 2023 investment in Vivacy and its global injectables business.
https://www.bridgepointgroup.com/investment-strategies/private-equity/portfolio/middle-market/healthcare/vivacy